Analysts expect Infinity Pharmaceuticals Inc. (NASDAQ:INFI) to post ($0.25) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Infinity Pharmaceuticals’ earnings, with estimates ranging from ($0.27) to ($0.22). Infinity Pharmaceuticals reported earnings per share of ($0.46) during the same quarter last year, which would indicate a positive year-over-year growth rate of 45.7%. The company is scheduled to announce its next quarterly earnings results on Tuesday, March 13th.
On average, analysts expect that Infinity Pharmaceuticals will report full year earnings of ($0.93) per share for the current fiscal year, with EPS estimates ranging from ($0.95) to ($0.90). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.07) per share, with EPS estimates ranging from ($1.10) to ($1.04). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Infinity Pharmaceuticals.
Infinity Pharmaceuticals (NASDAQ:INFI) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.06. Infinity Pharmaceuticals had a negative net margin of 118.40% and a negative return on equity of 50.76%. The firm had revenue of $6.00 million for the quarter, compared to analysts’ expectations of $14.70 million. During the same quarter last year, the company posted ($0.39) earnings per share.
Infinity Pharmaceuticals (NASDAQ:INFI) opened at $1.99 on Friday. Infinity Pharmaceuticals has a twelve month low of $0.93 and a twelve month high of $3.84. The stock has a market cap of $100.87, a PE ratio of -1.75 and a beta of 2.82.
In other Infinity Pharmaceuticals news, President Lawrence E. Bloch purchased 500,000 shares of the business’s stock in a transaction dated Wednesday, December 6th. The shares were bought at an average price of $1.81 per share, with a total value of $905,000.00. Following the completion of the acquisition, the president now owns 580,944 shares in the company, valued at approximately $1,051,508.64. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 6.81% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Platinum Investment Management Ltd. raised its holdings in Infinity Pharmaceuticals by 74.3% during the third quarter. Platinum Investment Management Ltd. now owns 1,411,832 shares of the biotechnology company’s stock worth $1,877,000 after purchasing an additional 601,600 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Infinity Pharmaceuticals by 32.7% during the second quarter. Dimensional Fund Advisors LP now owns 652,481 shares of the biotechnology company’s stock worth $1,024,000 after purchasing an additional 160,814 shares in the last quarter. FMR LLC bought a new stake in Infinity Pharmaceuticals during the second quarter worth approximately $349,000. Goldman Sachs Group Inc. raised its holdings in Infinity Pharmaceuticals by 75.0% during the second quarter. Goldman Sachs Group Inc. now owns 246,234 shares of the biotechnology company’s stock worth $387,000 after purchasing an additional 105,497 shares in the last quarter. Finally, Zacks Investment Management bought a new stake in Infinity Pharmaceuticals during the second quarter worth approximately $101,000. 54.29% of the stock is currently owned by hedge funds and other institutional investors.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with our FREE daily email newsletter.